Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electronic NDA Requirement Should Be Phased In Over 3 Years, Small Firms Say

Executive Summary

Small pharmaceutical companies favor FDA's proposal to move from paper to electronic filing of regulatory submissions but want a three-year grace period following the agency's issuance of a final rule

You may also be interested in...



FDA’s Technology Plan Will Wound, But Not Kill, Paper Submissions By 2012

FDA is seeking comment on the next steps the agency plans to take under the fourth extension of the Prescription Drug User Fee Act in order to move towards its vision of eliminating paper for the submission and review of all regulatory documents

FDA’s Technology Plan Will Wound, But Not Kill, Paper Submissions By 2012

FDA is seeking comment on the next steps the agency plans to take under the fourth extension of the Prescription Drug User Fee Act in order to move towards its vision of eliminating paper for the submission and review of all regulatory documents

User Fee Hike Will Give Sponsors Clarity On Label, Postmarketing Discussions

As part of its recommendations for the renewal of the user fee program, FDA is proposing refinements to its "74-day letters" to give sponsors a more detailed schedule of how the application review will proceed

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel